nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM4—osteoporosis	0.0363	0.208	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TPM4—osteoporosis	0.0309	0.177	CbGpPWpGaD
Dihydroxyaluminium—Acidosis—Calcium Acetate—osteoporosis	0.03	0.0378	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Calcitriol—osteoporosis	0.0279	0.0351	CcSEcCtD
Dihydroxyaluminium—Acidosis—Ergocalciferol—osteoporosis	0.0265	0.0334	CcSEcCtD
Dihydroxyaluminium—TNNC1—Muscle contraction—TPM4—osteoporosis	0.0244	0.14	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—ACTG1—osteoporosis	0.0182	0.104	CbGpPWpGaD
Dihydroxyaluminium—Venous thrombosis—Estropipate—osteoporosis	0.0175	0.022	CcSEcCtD
Dihydroxyaluminium—Toxicity to various agents—Estradiol—osteoporosis	0.0175	0.022	CcSEcCtD
Dihydroxyaluminium—Electrolyte imbalance—Pamidronate—osteoporosis	0.017	0.0214	CcSEcCtD
Dihydroxyaluminium—VDAC1—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.0158	1	CbGdCrCtD
Dihydroxyaluminium—Electrolyte imbalance—Zoledronate—osteoporosis	0.0155	0.0195	CcSEcCtD
Dihydroxyaluminium—Coma—Calcium Acetate—osteoporosis	0.0152	0.0191	CcSEcCtD
Dihydroxyaluminium—TNNC1—Muscle contraction—TLN1—osteoporosis	0.0146	0.0835	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—Muscle contraction—VCL—osteoporosis	0.0144	0.0824	CbGpPWpGaD
Dihydroxyaluminium—Polyuria—Ergocalciferol—osteoporosis	0.0121	0.0153	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Conjugated Estrogens—osteoporosis	0.0116	0.0145	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Pamidronate—osteoporosis	0.0114	0.0143	CcSEcCtD
Dihydroxyaluminium—Acidosis—Conjugated Estrogens—osteoporosis	0.0113	0.0142	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Estropipate—osteoporosis	0.0107	0.0135	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Ibandronate—osteoporosis	0.0103	0.013	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Conjugated Estrogens—osteoporosis	0.01	0.0126	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Risedronate—osteoporosis	0.00849	0.0107	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Estropipate—osteoporosis	0.00792	0.00996	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CCT2—osteoporosis	0.00768	0.044	CbGpPWpGaD
Dihydroxyaluminium—Polyuria—Calcitriol—osteoporosis	0.00733	0.00922	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Estropipate—osteoporosis	0.00723	0.0091	CcSEcCtD
Dihydroxyaluminium—Extravasation—Conjugated Estrogens—osteoporosis	0.00715	0.00899	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Conjugated Estrogens—osteoporosis	0.0071	0.00893	CcSEcCtD
Dihydroxyaluminium—Thirst—Ibandronate—osteoporosis	0.00691	0.00869	CcSEcCtD
Dihydroxyaluminium—Thirst—Calcitriol—osteoporosis	0.00676	0.0085	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TUBA1B—osteoporosis	0.00653	0.0375	CbGpPWpGaD
Dihydroxyaluminium—Urinary retention—Ibandronate—osteoporosis	0.00625	0.00786	CcSEcCtD
Dihydroxyaluminium—Dehydration—Calcitriol—osteoporosis	0.00598	0.00753	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Pamidronate—osteoporosis	0.00598	0.00752	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Pamidronate—osteoporosis	0.00595	0.00748	CcSEcCtD
Dihydroxyaluminium—Oedema—Calcium Acetate—osteoporosis	0.00593	0.00746	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Ethinyl Estradiol—osteoporosis	0.00586	0.00737	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Estradiol—osteoporosis	0.00568	0.00715	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Conjugated Estrogens—osteoporosis	0.00558	0.00702	CcSEcCtD
Dihydroxyaluminium—Hypotension—Calcium Acetate—osteoporosis	0.00554	0.00697	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Conjugated Estrogens—osteoporosis	0.00526	0.00661	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Conjugated Estrogens—osteoporosis	0.00523	0.00658	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPL24—osteoporosis	0.00522	0.0299	CbGpPWpGaD
Dihydroxyaluminium—Pain—Calcium Acetate—osteoporosis	0.00507	0.00638	CcSEcCtD
Dihydroxyaluminium—Thirst—Zoledronate—osteoporosis	0.00494	0.00622	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Conjugated Estrogens—osteoporosis	0.00478	0.00601	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Estropipate—osteoporosis	0.00475	0.00598	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Raloxifene—osteoporosis	0.0046	0.00579	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TLN1—osteoporosis	0.00459	0.0263	CbGpPWpGaD
Dihydroxyaluminium—Visual impairment—Estropipate—osteoporosis	0.00457	0.00575	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Risedronate—osteoporosis	0.00456	0.00574	CcSEcCtD
Dihydroxyaluminium—Pain—Ergocalciferol—osteoporosis	0.00448	0.00564	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—REN—osteoporosis	0.00441	0.0253	CbGpPWpGaD
Dihydroxyaluminium—Dehydration—Zoledronate—osteoporosis	0.00437	0.0055	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Calcium Acetate—osteoporosis	0.00437	0.0055	CcSEcCtD
Dihydroxyaluminium—Dehydration—Conjugated Estrogens—osteoporosis	0.00421	0.0053	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Estradiol—osteoporosis	0.00421	0.00529	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Estradiol—osteoporosis	0.00419	0.00527	CcSEcCtD
Dihydroxyaluminium—Polyuria—Estradiol—osteoporosis	0.00413	0.00519	CcSEcCtD
Dihydroxyaluminium—Chills—Ibandronate—osteoporosis	0.00408	0.00513	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Calcium Acetate—osteoporosis	0.00406	0.0051	CcSEcCtD
Dihydroxyaluminium—Back pain—Estropipate—osteoporosis	0.00399	0.00502	CcSEcCtD
Dihydroxyaluminium—Dizziness—Calcium Acetate—osteoporosis	0.00392	0.00493	CcSEcCtD
Dihydroxyaluminium—Infection—Etidronic acid—osteoporosis	0.00387	0.00487	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Ethinyl Estradiol—osteoporosis	0.00385	0.00485	CcSEcCtD
Dihydroxyaluminium—Back pain—Ibandronate—osteoporosis	0.00383	0.00482	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Estradiol—osteoporosis	0.00383	0.00481	CcSEcCtD
Dihydroxyaluminium—Vomiting—Calcium Acetate—osteoporosis	0.00377	0.00474	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Risedronate—osteoporosis	0.00376	0.00472	CcSEcCtD
Dihydroxyaluminium—Vertigo—Estropipate—osteoporosis	0.00371	0.00466	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Ethinyl Estradiol—osteoporosis	0.0037	0.00466	CcSEcCtD
Dihydroxyaluminium—Vertigo—Alendronate—osteoporosis	0.00365	0.00459	CcSEcCtD
Dihydroxyaluminium—VDAC2—uterus—osteoporosis	0.00365	0.25	CbGeAlD
Dihydroxyaluminium—Vertigo—Raloxifene—osteoporosis	0.00359	0.00452	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Pamidronate—osteoporosis	0.00357	0.00449	CcSEcCtD
Dihydroxyaluminium—Vertigo—Ibandronate—osteoporosis	0.00356	0.00447	CcSEcCtD
Dihydroxyaluminium—Nausea—Calcium Acetate—osteoporosis	0.00352	0.00443	CcSEcCtD
Dihydroxyaluminium—Oedema—Estropipate—osteoporosis	0.00337	0.00424	CcSEcCtD
Dihydroxyaluminium—Convulsion—Calcitriol—osteoporosis	0.00336	0.00422	CcSEcCtD
Dihydroxyaluminium—Infection—Estropipate—osteoporosis	0.00335	0.00421	CcSEcCtD
Dihydroxyaluminium—Infection—Alendronate—osteoporosis	0.0033	0.00415	CcSEcCtD
Dihydroxyaluminium—Infection—Raloxifene—osteoporosis	0.00324	0.00408	CcSEcCtD
Dihydroxyaluminium—Back pain—Ethinyl Estradiol—osteoporosis	0.00324	0.00407	CcSEcCtD
Dihydroxyaluminium—Infection—Ibandronate—osteoporosis	0.00321	0.00404	CcSEcCtD
Dihydroxyaluminium—Chills—Pamidronate—osteoporosis	0.0032	0.00402	CcSEcCtD
Dihydroxyaluminium—Back pain—Risedronate—osteoporosis	0.00316	0.00397	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Conjugated Estrogens—osteoporosis	0.00314	0.00395	CcSEcCtD
Dihydroxyaluminium—Nausea—Ergocalciferol—osteoporosis	0.00311	0.00391	CcSEcCtD
Dihydroxyaluminium—Urticaria—Etidronic acid—osteoporosis	0.00309	0.00389	CcSEcCtD
Dihydroxyaluminium—VDAC3—uterus—osteoporosis	0.00304	0.208	CbGeAlD
Dihydroxyaluminium—Visual impairment—Conjugated Estrogens—osteoporosis	0.00302	0.0038	CcSEcCtD
Dihydroxyaluminium—Back pain—Pamidronate—osteoporosis	0.003	0.00377	CcSEcCtD
Dihydroxyaluminium—Vertigo—Risedronate—osteoporosis	0.00293	0.00369	CcSEcCtD
Dihydroxyaluminium—Chills—Zoledronate—osteoporosis	0.00292	0.00367	CcSEcCtD
Dihydroxyaluminium—VDAC1—uterus—osteoporosis	0.00289	0.198	CbGeAlD
Dihydroxyaluminium—Pain—Estropipate—osteoporosis	0.00288	0.00362	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Etidronic acid—osteoporosis	0.00287	0.00361	CcSEcCtD
Dihydroxyaluminium—Pain—Alendronate—osteoporosis	0.00284	0.00357	CcSEcCtD
Dihydroxyaluminium—Pain—Raloxifene—osteoporosis	0.00279	0.00351	CcSEcCtD
Dihydroxyaluminium—Pain—Ibandronate—osteoporosis	0.00276	0.00347	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ACE—osteoporosis	0.00275	0.0158	CbGpPWpGaD
Dihydroxyaluminium—Back pain—Zoledronate—osteoporosis	0.00274	0.00345	CcSEcCtD
Dihydroxyaluminium—Oedema—Ethinyl Estradiol—osteoporosis	0.00273	0.00343	CcSEcCtD
Dihydroxyaluminium—Infection—Ethinyl Estradiol—osteoporosis	0.00271	0.00341	CcSEcCtD
Dihydroxyaluminium—Pain—Calcitriol—osteoporosis	0.0027	0.0034	CcSEcCtD
Dihydroxyaluminium—Convulsion—Pamidronate—osteoporosis	0.00269	0.00338	CcSEcCtD
Dihydroxyaluminium—Urticaria—Estropipate—osteoporosis	0.00268	0.00337	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Zoledronate—osteoporosis	0.00267	0.00336	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etidronic acid—osteoporosis	0.00266	0.00335	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Estropipate—osteoporosis	0.00266	0.00335	CcSEcCtD
Dihydroxyaluminium—Infection—Risedronate—osteoporosis	0.00265	0.00333	CcSEcCtD
Dihydroxyaluminium—Back pain—Conjugated Estrogens—osteoporosis	0.00264	0.00332	CcSEcCtD
Dihydroxyaluminium—Urticaria—Alendronate—osteoporosis	0.00264	0.00332	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Alendronate—osteoporosis	0.00262	0.0033	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Raloxifene—osteoporosis	0.00258	0.00324	CcSEcCtD
Dihydroxyaluminium—VDAC3—bone marrow—osteoporosis	0.00258	0.176	CbGeAlD
Dihydroxyaluminium—Vision blurred—Conjugated Estrogens—osteoporosis	0.00257	0.00323	CcSEcCtD
Dihydroxyaluminium—Urticaria—Ibandronate—osteoporosis	0.00257	0.00323	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Ibandronate—osteoporosis	0.00255	0.00321	CcSEcCtD
Dihydroxyaluminium—Vertigo—Zoledronate—osteoporosis	0.00255	0.0032	CcSEcCtD
Dihydroxyaluminium—Oedema—Pamidronate—osteoporosis	0.00253	0.00318	CcSEcCtD
Dihydroxyaluminium—Infection—Pamidronate—osteoporosis	0.00251	0.00316	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Estradiol—osteoporosis	0.00251	0.00316	CcSEcCtD
Dihydroxyaluminium—Urticaria—Calcitriol—osteoporosis	0.00251	0.00316	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Calcitriol—osteoporosis	0.0025	0.00314	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Estropipate—osteoporosis	0.00248	0.00312	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etidronic acid—osteoporosis	0.00248	0.00311	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Pamidronate—osteoporosis	0.00247	0.00311	CcSEcCtD
Dihydroxyaluminium—Convulsion—Zoledronate—osteoporosis	0.00245	0.00309	CcSEcCtD
Dihydroxyaluminium—VDAC1—bone marrow—osteoporosis	0.00245	0.168	CbGeAlD
Dihydroxyaluminium—Vertigo—Conjugated Estrogens—osteoporosis	0.00245	0.00308	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Alendronate—osteoporosis	0.00244	0.00307	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Estradiol—osteoporosis	0.00242	0.00304	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Ibandronate—osteoporosis	0.00238	0.00299	CcSEcCtD
Dihydroxyaluminium—Hypotension—Pamidronate—osteoporosis	0.00237	0.00297	CcSEcCtD
Dihydroxyaluminium—Convulsion—Conjugated Estrogens—osteoporosis	0.00236	0.00297	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Calcitriol—osteoporosis	0.00233	0.00293	CcSEcCtD
Dihydroxyaluminium—Nausea—Etidronic acid—osteoporosis	0.00231	0.00291	CcSEcCtD
Dihydroxyaluminium—Oedema—Zoledronate—osteoporosis	0.00231	0.00291	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Estropipate—osteoporosis	0.00231	0.0029	CcSEcCtD
Dihydroxyaluminium—Infection—Zoledronate—osteoporosis	0.0023	0.00289	CcSEcCtD
Dihydroxyaluminium—Pain—Risedronate—osteoporosis	0.00228	0.00286	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Alendronate—osteoporosis	0.00227	0.00286	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Zoledronate—osteoporosis	0.00226	0.00284	CcSEcCtD
Dihydroxyaluminium—Chills—Estradiol—osteoporosis	0.00225	0.00283	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Raloxifene—osteoporosis	0.00223	0.00281	CcSEcCtD
Dihydroxyaluminium—Dizziness—Estropipate—osteoporosis	0.00223	0.0028	CcSEcCtD
Dihydroxyaluminium—Oedema—Conjugated Estrogens—osteoporosis	0.00223	0.0028	CcSEcCtD
Dihydroxyaluminium—Infection—Conjugated Estrogens—osteoporosis	0.00221	0.00278	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Ibandronate—osteoporosis	0.00221	0.00278	CcSEcCtD
Dihydroxyaluminium—Dizziness—Alendronate—osteoporosis	0.00219	0.00276	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Conjugated Estrogens—osteoporosis	0.00217	0.00273	CcSEcCtD
Dihydroxyaluminium—Urticaria—Ethinyl Estradiol—osteoporosis	0.00217	0.00273	CcSEcCtD
Dihydroxyaluminium—Pain—Pamidronate—osteoporosis	0.00216	0.00272	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Calcitriol—osteoporosis	0.00216	0.00272	CcSEcCtD
Dihydroxyaluminium—Hypotension—Zoledronate—osteoporosis	0.00216	0.00272	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00216	0.00271	CcSEcCtD
Dihydroxyaluminium—Dizziness—Raloxifene—osteoporosis	0.00216	0.00271	CcSEcCtD
Dihydroxyaluminium—Vomiting—Estropipate—osteoporosis	0.00214	0.00269	CcSEcCtD
Dihydroxyaluminium—Dizziness—Ibandronate—osteoporosis	0.00214	0.00269	CcSEcCtD
Dihydroxyaluminium—Urticaria—Risedronate—osteoporosis	0.00212	0.00266	CcSEcCtD
Dihydroxyaluminium—Back pain—Estradiol—osteoporosis	0.00211	0.00266	CcSEcCtD
Dihydroxyaluminium—Vomiting—Alendronate—osteoporosis	0.00211	0.00265	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Risedronate—osteoporosis	0.0021	0.00265	CcSEcCtD
Dihydroxyaluminium—Hypotension—Conjugated Estrogens—osteoporosis	0.00208	0.00262	CcSEcCtD
Dihydroxyaluminium—Vomiting—Raloxifene—osteoporosis	0.00207	0.00261	CcSEcCtD
Dihydroxyaluminium—Vomiting—Ibandronate—osteoporosis	0.00205	0.00258	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.00201	0.00253	CcSEcCtD
Dihydroxyaluminium—Vomiting—Calcitriol—osteoporosis	0.00201	0.00253	CcSEcCtD
Dihydroxyaluminium—Nausea—Estropipate—osteoporosis	0.002	0.00252	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Pamidronate—osteoporosis	0.002	0.00252	CcSEcCtD
Dihydroxyaluminium—Pain—Zoledronate—osteoporosis	0.00198	0.00249	CcSEcCtD
Dihydroxyaluminium—Nausea—Alendronate—osteoporosis	0.00197	0.00248	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Risedronate—osteoporosis	0.00196	0.00247	CcSEcCtD
Dihydroxyaluminium—Vertigo—Estradiol—osteoporosis	0.00196	0.00247	CcSEcCtD
Dihydroxyaluminium—Nausea—Raloxifene—osteoporosis	0.00194	0.00244	CcSEcCtD
Dihydroxyaluminium—Nausea—Ibandronate—osteoporosis	0.00192	0.00241	CcSEcCtD
Dihydroxyaluminium—Pain—Conjugated Estrogens—osteoporosis	0.0019	0.00239	CcSEcCtD
Dihydroxyaluminium—Nausea—Calcitriol—osteoporosis	0.00188	0.00236	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.00187	0.00235	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Pamidronate—osteoporosis	0.00186	0.00235	CcSEcCtD
Dihydroxyaluminium—Urticaria—Zoledronate—osteoporosis	0.00184	0.00231	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Zoledronate—osteoporosis	0.00183	0.0023	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Risedronate—osteoporosis	0.00182	0.00229	CcSEcCtD
Dihydroxyaluminium—Dizziness—Ethinyl Estradiol—osteoporosis	0.00181	0.00227	CcSEcCtD
Dihydroxyaluminium—Oedema—Estradiol—osteoporosis	0.00178	0.00224	CcSEcCtD
Dihydroxyaluminium—Infection—Estradiol—osteoporosis	0.00177	0.00223	CcSEcCtD
Dihydroxyaluminium—Urticaria—Conjugated Estrogens—osteoporosis	0.00177	0.00222	CcSEcCtD
Dihydroxyaluminium—Dizziness—Risedronate—osteoporosis	0.00176	0.00221	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Conjugated Estrogens—osteoporosis	0.00176	0.00221	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Estradiol—osteoporosis	0.00174	0.00219	CcSEcCtD
Dihydroxyaluminium—Vomiting—Ethinyl Estradiol—osteoporosis	0.00174	0.00218	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Pamidronate—osteoporosis	0.00173	0.00218	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—LEP—osteoporosis	0.00171	0.00981	CbGpPWpGaD
Dihydroxyaluminium—Hypersensitivity—Zoledronate—osteoporosis	0.0017	0.00214	CcSEcCtD
Dihydroxyaluminium—Vomiting—Risedronate—osteoporosis	0.00169	0.00213	CcSEcCtD
Dihydroxyaluminium—Dizziness—Pamidronate—osteoporosis	0.00167	0.0021	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.00164	0.00206	CcSEcCtD
Dihydroxyaluminium—Nausea—Ethinyl Estradiol—osteoporosis	0.00162	0.00204	CcSEcCtD
Dihydroxyaluminium—Vomiting—Pamidronate—osteoporosis	0.00161	0.00202	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Zoledronate—osteoporosis	0.00158	0.00199	CcSEcCtD
Dihydroxyaluminium—Nausea—Risedronate—osteoporosis	0.00158	0.00199	CcSEcCtD
Dihydroxyaluminium—Dizziness—Zoledronate—osteoporosis	0.00153	0.00192	CcSEcCtD
Dihydroxyaluminium—Pain—Estradiol—osteoporosis	0.00152	0.00192	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Conjugated Estrogens—osteoporosis	0.00152	0.00192	CcSEcCtD
Dihydroxyaluminium—Nausea—Pamidronate—osteoporosis	0.0015	0.00189	CcSEcCtD
Dihydroxyaluminium—Dizziness—Conjugated Estrogens—osteoporosis	0.00147	0.00185	CcSEcCtD
Dihydroxyaluminium—Vomiting—Zoledronate—osteoporosis	0.00147	0.00185	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—POMC—osteoporosis	0.00147	0.00842	CbGpPWpGaD
Dihydroxyaluminium—Vomiting—Conjugated Estrogens—osteoporosis	0.00142	0.00178	CcSEcCtD
Dihydroxyaluminium—Urticaria—Estradiol—osteoporosis	0.00142	0.00178	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGF1—osteoporosis	0.00141	0.0081	CbGpPWpGaD
Dihydroxyaluminium—Body temperature increased—Estradiol—osteoporosis	0.00141	0.00177	CcSEcCtD
Dihydroxyaluminium—Nausea—Zoledronate—osteoporosis	0.00137	0.00173	CcSEcCtD
Dihydroxyaluminium—Nausea—Conjugated Estrogens—osteoporosis	0.00132	0.00166	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Estradiol—osteoporosis	0.00131	0.00165	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Estradiol—osteoporosis	0.00122	0.00153	CcSEcCtD
Dihydroxyaluminium—Dizziness—Estradiol—osteoporosis	0.00118	0.00148	CcSEcCtD
Dihydroxyaluminium—Vomiting—Estradiol—osteoporosis	0.00113	0.00142	CcSEcCtD
Dihydroxyaluminium—Nausea—Estradiol—osteoporosis	0.00106	0.00133	CcSEcCtD
